Leukemia, Myeloid: all 2,432 studies
Page 12 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid LeukemiaStatus unknownNCT04215822
- Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual DiseaseStatus unknownNCT04209712Early Phase 1
- Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04202003Phase 1/2
- Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid NeoplasmsTerminatedNCT04196010Phase 1
- Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)Status unknownNCT04187495Phase 1
- A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 MutationCompletedNCT04176393Phase 1
- Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedNCT04172844Phase 1
- D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly PatientsStatus unknownNCT04168138Not applicable
- Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDSTerminatedNCT04166929Phase 2
- Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous LeukemiaCompletedNCT04158726Not applicable
- CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT04156256Early Phase 1
- A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04155580Phase 1
- Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CPStatus unknownNCT04155411Phase 4
- Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia PatientsStatus unknownNCT04150471
- Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaActive, not recruitingNCT04147533Phase 2
- Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid LeukemiaStatus unknownNCT04133220
- The Absorption, Metabolism and Excretion of [14C] HQP1351 in HumansCompletedNCT04126707Phase 1
- A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT04126681Phase 2
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT04113616Phase 1/2
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
- Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid LeukemiaWithdrawnNCT04106076Phase 1
- Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular ResponseStatus unknownNCT04104035
- A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT04100330Phase 2
- Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)TerminatedNCT04093505Phase 3
- A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life SettingCompletedNCT04089839
- Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML PatientsStatus unknownNCT04087967Phase 3
- Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
- LY3214996 in Patients With AML Who Are Not Candidates for Standard TherapyCompletedNCT04081259Phase 1
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedNCT04075747Phase 1
- Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2Status unknownNCT04070807
- IA14 Induction in Young Acute Myeloid LeukemiaStatus unknownNCT04069208Phase 2
- Randomized Clinical Study Assessing Haplo vs. URD in AMLTerminatedNCT04067180Not applicable
- Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment ResultsStatus unknownNCT04060485
- An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic MalignanciesCompletedNCT04052126Not applicable
- Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)CompletedNCT04048564
- Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid LeukemiaStatus unknownNCT04043676Phase 2
- Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological DiseaseCompletedNCT04039100Not applicable
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyActive, not recruitingNCT04027309Phase 3
- Medium Dose of Cytarabine and MitoxantroneStatus unknownNCT04024241
- FT516 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04023071Phase 1
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04022785Phase 1
- A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML PatientsStatus unknownNCT04015024Phase 2
- Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.Status unknownNCT04014881Phase 1
- Collect and Assess Tissue Samples From Subjects With Hematologic MalignancyCompletedNCT04014764
- ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaWithdrawnNCT04013880Phase 1/2
- Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid LeukaemiaStatus unknownNCT04008381Phase 1
- AML Expressive WritingTerminatedNCT04006496Not applicable
- CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03985007Phase 2
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic TransplantCompletedNCT03961919Phase 2
- INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTSStatus unknownNCT03955848Not applicable
- Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationTerminatedNCT03951961Phase 2
- Nilotinib for First-line Newly Diagnosed CML-CP PatientsStatus unknownNCT03942094Phase 3
- Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any DoseActive, not recruitingNCT03933852
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSActive, not recruitingNCT03927261Phase 1
- MIF Involvement in AMLActive, not recruitingNCT03918655
- A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT03915379Phase 1
- Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AMLStatus unknownNCT03913312Phase 1/2
- Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase InhibitorStatus unknownNCT03907670
- CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
- Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AMLWithdrawnNCT03904069Phase 1
- Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75CompletedNCT03902665Phase 2
- SRSF2 Gene Mutation in Patients With t-MDS/AMLCompletedNCT03894852
- Precision Dosing of Tyrosine Kinase Inhibitors in CML PatientsCompletedNCT03885830
- Gamma Delta T Cells in AMLStatus unknownNCT03885076
- A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationStatus unknownNCT03883100Phase 2
- Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaCompletedNCT03882281Phase 1
- Investigation of the Gut Microbiota in Patients With Acute Myeloid LeukemiaCompletedNCT03881826Not applicable
- Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene MutationWithdrawnNCT03881735Phase 2
- CPX-351+GO in Subjects 55 Years Old, or Older, With AMLTerminatedNCT03878927Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Ex Vivo Drug Sensitivity Testing and Mutation ProfilingCompletedNCT03860376
- A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AMLStatus unknownNCT03846362Phase 3
- Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From DiagnosisCompletedNCT03831776Phase 2
- The Effects of AMPC in the Treatments of Refractory or Relapsed AMLStatus unknownNCT03825146Phase 1
- Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult PatientsCompletedNCT03823352Phase 2
- Bisantrene for Relapsed /Refractory AMLCompletedNCT03820908Phase 2
- Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1
- Study in Patients With Chronic LeukemiaTerminatedNCT03807479Phase 2
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1
- Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid LeukemiaTerminatedNCT03806192Not applicable
- A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
- Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic LeukemiaStatus unknownNCT03796390Phase 1
- CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT03795779Early Phase 1
- Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)CompletedNCT03790072Phase 1
- Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid LeukemiaActive, not recruitingNCT03789981
- A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedNCT03787498Phase 1
- Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03779854Phase 2
- Dexamethasone in Refractory or First Relapsed Acute Myeloid LeukemiaTerminatedNCT03765541Phase 3
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute LeukemiasTerminatedNCT03761069Phase 1
- Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03760523Phase 1
- HDM201 Added to CT in R/R or Newly Diagnosed AMLWithdrawnNCT03760445Phase 1/2
- Cardiovascular Function in Acute LeukemiaCompletedNCT03760237
- Long-term Outcomes for Acute Myeloid Leukemia PatientsStatus unknownNCT03755856
- TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid LeukemiaWithdrawnNCT03752138Phase 1
- Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive QuizartinibNo longer availableNCT03746912
- Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortalityTerminatedNCT03746054Phase 3
- Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03745352Phase 2
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2